Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

Company Overview - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [3] - The company's lead product, Olvi-Vec, is currently being evaluated in multiple clinical trials for various cancer types, including ovarian cancer and non-small-cell lung cancer [3] Upcoming Events - Thomas Zindrick, President, CEO, and Chairman, along with CFO Matt Pulisic, will participate in a fireside chat at H.C. Wainwright & Co's Annual Global Investment Conference on September 9, 2025 [1] - The session will be moderated by Biotech Equity Research Analyst Emily Bodnar and is scheduled to begin at 2:30 p.m. ET [2] Clinical Trials - Olvi-Vec is being evaluated in two U.S.-based clinical trials: - OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer [3] - VIRO-25, a Phase 2 trial for non-small-cell lung cancer [3] - Additionally, a China-based Phase 1b trial is assessing Olvi-Vec for recurrent small-cell lung cancer [3] Contact Information - For investor and media inquiries, contact Ankit Bhargava at Allele Communications, LLC [4]